Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bluejeans who wrote (19277)	4/18/1998 1:36:00 AM
From: WTDEC	Respond to of 32384

Bob, thanks for posting the URL for the RedHerring articles. Everyone invested in biotechs should read them. They are the same ones I mentioned about 2 weeks ago when the hard copy of the magazine came out. Regards, W

To: bluejeans who wrote (19277)	4/19/1998 2:02:00 AM
From: bluejeans	Read Replies (2) \| Respond to of 32384

Ligand's research focuses on finding or engineering compounds (ligands) to bind with intracellular and STAT receptors to give instructions to cells. The primary applications for these products are cancer treatment and hormone therapy without negative side effects. The advantages of the Ligand approach are that the compounds which they research directly stimulate the basic control mechanisms of cells and thus can often act with few side effects. These compounds are also relatively easy to manufacture and can be easily administered in both oral and topical forms. Disadvantages of the approach include the complexity of the intracellular workings Ligand seeks to manipulate and the many potential complications involved with receptor technology. The bright side of the disadvantage is it should reduce competition.<G>